Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study is a research paper published in Neurotherapeutics (2022). On theSindex it has a DataRank of 4.7. It has been cited 168 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.769
From this paper's citation signal
Citation Network Contribution
4.0
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NINDS NIH HHS
Grant: R01 NS105479
National Institutes of Health
Grant: 5R01NS105479-05
Pre-Symptomatic Familial ALS (Pre-fALS) Study - Prelude to a Treatment Trial
Biogen
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals